Last reviewed · How we verify
BioXcel Therapeutics Inc — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
1 Phase 2
6 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sublingual film containing Igalmi | Sublingual film containing Igalmi | marketed | Atypical antipsychotic | Dopamine D2 receptor, Serotonin 5-HT2A receptor | Psychiatry | |
| Placebo film | Placebo film | phase 3 |
Therapeutic area mix
- Neurology · 1
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Acacia Pharma Ltd · 1 shared drug class
- Alexza Pharmaceuticals, Inc. · 1 shared drug class
- Alkermes, Inc. · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- AstraZeneca · 1 shared drug class
- Benaroya Research Institute · 1 shared drug class
- CCTU · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for BioXcel Therapeutics Inc:
- BioXcel Therapeutics Inc pipeline updates — RSS
- BioXcel Therapeutics Inc pipeline updates — Atom
- BioXcel Therapeutics Inc pipeline updates — JSON
Cite this brief
Drug Landscape (2026). BioXcel Therapeutics Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bioxcel-therapeutics-inc. Accessed 2026-05-16.